Propanc Health Group, an emerging healthcare company focused on developing treatments for cancer, has entered a contract manufacturing agreement with AmatsiQBiologicals, based in Gent, Belgium, for the development and GMP production of certain enzymes for development purposes, including first-in-man studies for the company’s lead product, PRP.   PRP is a novel formulation of two proenzymes mixed in a synergistic ratio to target cancer stem cells in solid tumors. The GMP manufacture of PR...